본문 바로가기
  • Home

Sulforaphane Inhibits ICAM-1 Expression and Monocyte Adhesion in Human Bladder Cancer T24 Cells

  • Anatomy & Biological Anthropology
  • Abbr : Anat Biol Anthropol
  • 2021, 34(1), pp.21~30
  • DOI : 10.11637/aba.2021.34.1.21
  • Publisher : 대한체질인류학회
  • Research Area : Medicine and Pharmacy > Anatomy
  • Received : January 14, 2021
  • Accepted : February 16, 2021
  • Published : March 31, 2021

AHN KYU YOUN ORD ID 1 Pham Ngoc Khoi 2 youngsuk Cho ORD ID 1 SHINAN Li ORD ID 1 Dhiraj Kumar Sah 3 Yong Xia 4 Jung Young Do ORD ID 1

1전남대학교
2Department of Histology - Embryology and Genetics, Faculty of Basic Medical Sciences, Pham Ngoc Thac
3Department of Biochemistry, Chonnam National University Medical School
4Key Laboratory of Precision Oncology of Shandong Higher Education, Institute of Precision Medicine,

Accredited

ABSTRACT

Intracellular adhesion molecule-1 (ICAM-1) belongs to the immunoglobulin-like superfamily of adhesion molecules that mediate cell adhesion to other cells, and ICAM-1 is involved in cancer progression and recurrence. Since the ICAM-1 is considered as one of the therapeutic target against bladder cancer, we examined whether sulforaphane, an aliphatic isothiocyanate, could inhibit ICAM-1 expression in bladder cancer T24 cells. Sulforaphane inhibited phorbol 12-myristate 13-acetate (PMA)-induced ICAM-1 expression at the mRNA and protein levels in human bladder cancer cells, as revealed by reverse transcriptase polymerase chain reaction and western blot analyses, respectively. Specific inhibitor studies have shown that the transcription factors, activator protein-1 (AP-1) and nuclear factor-kappa B (NF-κB), are involved in PMA-induced ICAM-1 expression. We found that sulforaphane inhibited the activation of both AP-1 and NF-κB induced by PMA in bladder cancer cells. Interestingly, we also found that sulforaphane abrogated PMA-induced THP-1 monocyte adhesion to bladder cancer cells. Collectively, our results provide experimental evidence that sulforaphane could serve as a new therapeutic candidate against bladder cancer.

Citation status

* References for papers published after 2023 are currently being built.